KALA BIO, Inc.

Industry

  • Pharmaceuticals
    • Drug Delivery
      • Site Specific
      • Topical Delivery
    • Specialty Pharmaceuticals
  • Biotechnology
    • Nanotechnology, Chips, etc.

Other Names/Subsidiaries

  • Combangio, Inc.
  • Kala Pharmaceuticals, Inc.
  • Combangio
See more in Biomedtracker

Latest on KALA BIO, Inc.

In Vivo

Dealmaking Quarterly Statistics, Q3 2022

 
• By Deanna Kamienski and Maureen Riordan

Biopharma Acquisitions Biopharma merger and acquisition value for the third quarter of 2022 reached $15.4bn from 41 transactions, 21 of which had disclosed values. Four M&A transactions hit or exceede

Medtech Insight

BTIG Analyst Zooms Into Alcon’s Revamp Into ‘Building A Pharma Company Inside A Device Company’

 
• By Marion Webb

After its spin-out from Novartis AG in 2019, ophthalmology specialist Alcon Inc. has steadily expanded its pharmaceutical portfolio and formed a dedicated sales channel to focus specifically on ey

Scrip

Alcon Buys Aerie, Reaffirming Commitment To Pharma Space

 
• By Jessica Merrill

Ophthalmology specialist Alcon Inc. will buy Aerie Pharmaceuticals, Inc. for roughly $770m, gaining two commercial products for glaucoma, a Phase III drug candidate for dry eye disease and other e

Scrip

Deal Watch: Innoviva To Buy The Rest Of Entasis For Enterprise Value Of $113m

 
• By Joseph Haas and Ayisha Sharma

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Innoviva Acquisition Of Entasis Leaves